Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971409 · ClinicalTrials.gov registry record · Phase 2
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
A Phase 2 study of Invasive Breast Carcinoma and Stage IV Breast Cancer, sponsored by Laura Huppert, MD, BA.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 12
- Study locations
NCT03971409 is a Phase 2 study of Invasive Breast Carcinoma and Stage IV Breast Cancer that is actively recruiting participants, run by Laura Huppert, MD, BA. The registered enrollment target is 150 participants, below the 482-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (69% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT03971409, a Phase 2 study of Invasive Breast Carcinoma and Stage IV Breast Cancer, is actively recruiting participants, sponsored by Laura Huppert, MD, BA.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Conditions Studied
Interventions
- DRUG Liposomal Doxorubicin
- DRUG Avelumab
- DRUG Binimetinib
- BIOLOGICAL Anti-OX40 Antibody PF-04518600
- BIOLOGICAL Utomilumab
Study Locations (12)
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
- Duke Cancer Institute - Durham
Alabama
- O'Neal Comprehensive Cancer Center - Birmingham
California
- University of California, San Francisco - San Francisco
District of Columbia
- Georgetown University - Washington D.C.
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Evergreen Park
Maryland
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03971409
The ClinicalTrials.gov registry entry for NCT03971409 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (69% lower). The listed sponsor is Laura Huppert, MD, BA, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Liposomal Doxorubicin is the first listed.
NCT03971409 reports 12 study locations spanning 11 distinct geographic areas - top geographies include North Carolina, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03971409 about?
NCT03971409 is a clinical study titled "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer". This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (u...
What is the current status of trial NCT03971409?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2019-07-08. Estimated completion is 2026-06-30.
What conditions does trial NCT03971409 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage IV Breast Cancer, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer.
What interventions are being tested in trial NCT03971409?
The interventions under investigation include: Liposomal Doxorubicin (DRUG), Avelumab (DRUG), Binimetinib (DRUG), Anti-OX40 Antibody PF-04518600 (BIOLOGICAL), Utomilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03971409?
This trial is sponsored by Laura Huppert, MD, BA, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03971409 being conducted?
This trial has 12 study locations across Alabama, California, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.